Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491309 | 0.89 | POLB (0.49) | POLBTP53LMNAMAPT | |
| SCHEMBL16468271 | 0.88 | POLB (0.50) | POLBTP53LMNAMAPT | |
| SCHEMBL16612234 | 0.86 | TP53 (0.44) | POLBTP53LMNAMAPT | |
| SCHEMBL16468052 | 0.81 | POLB (0.46) | POLBTP53LMNAMAPT | |
| SCHEMBL16468474 | 0.81 | POLB (0.46) | POLBTP53LMNAMAPT | |
| SCHEMBL16468465 | 0.81 | POLB (0.46) | POLBTP53LMNAMAPT | |
| SCHEMBL12803047 | 0.80 | TP53 (0.60) | POLBTP53LMNAMAPT | |
| SCHEMBL16611937 | 0.80 | POLB (0.47) | POLBTP53LMNAMAPT | |
| SCHEMBL1534266 | 0.79 | TP53 (0.59) | POLBTP53LMNAMAPT | |
| SCHEMBL16491313 | 0.79 | TP53 (0.46) | POLBTP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2857404-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | POLB 3415/4885TP53 930/4885LMNA 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.